Astellas UK’s suspension from membership of the ABPI extended

​Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016.  This has been extended for a further 12 months.

Press Release 23 June 2017

The original suspension was in connection with a serious matter which came to light during the PMCPA consideration of two complaints and, as a consequence, Astellas UK and Astellas Europe were reported to the ABPI Board.
In addition, three cases arising from voluntary admissions made between October 2016 and February 2017, Case AUTH/2883/10/16 and Cases AUTH/2939/2/17 and AUTH/2940/2/17, were reported to the Code of Practice Appeal Board which reported them to the ABPI Board.
Both companies have been audited, re-audited and will be re-audited in October 2017.
Full details can be found in the case reports, Case AUTH/2780/7/15 and AUTH/2747/1/15​, Case AUTH/2883/10/16 and Cases AUTH/2939/2/17 and AUTH/2940/2/17.
The ABPI issued a press release which has since been updated here